Clinical Trials | April 14, 2026
AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial
Highlights Mirvetuximab-based regimen promise
Highlights Mirvetuximab-based regimen promise
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
On-site medical room brings preventive care, routine consultations, and diagnostics closer to residents
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The Stealth AXiS surgical navigation system was recently cleared by the US Food and Drug Administration (FDA) for cranial procedures in the United States
Subscribe To Our Newsletter & Stay Updated
